Pharsight

Viberzi patents expiration

VIBERZI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10213415 ALLERGAN HOLDINGS Compounds as opioid receptor modulators
Mar, 2025

(11 months from now)

US7786158 ALLERGAN HOLDINGS Compounds as opioid receptor modulators
Mar, 2025

(11 months from now)

US8609709 ALLERGAN HOLDINGS Compounds as opioid receptor modulators
Mar, 2025

(11 months from now)

US9115091 ALLERGAN HOLDINGS Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Jul, 2028

(4 years from now)

US8691860 ALLERGAN HOLDINGS Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Jul, 2028

(4 years from now)

US7741356 ALLERGAN HOLDINGS Compounds as opioid receptor modulators
May, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9205076 ALLERGAN HOLDINGS Compounds as opioid receptor modulators
Mar, 2025

(11 months from now)

US8344011 ALLERGAN HOLDINGS Compounds as opioid receptor modulators
Mar, 2025

(11 months from now)

US9700542 ALLERGAN HOLDINGS Compounds as opioid receptor modulators
Mar, 2025

(11 months from now)

US8772325 ALLERGAN HOLDINGS Compounds as opioid receptor modulators
Mar, 2025

(11 months from now)

US9364489 ALLERGAN HOLDINGS Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Jul, 2028

(4 years from now)

US9789125 ALLERGAN HOLDINGS Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Jul, 2028

(4 years from now)

US9675587 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

US11090291 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

US11229627 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

US11007179 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

US11160792 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

US11311516 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

US10188632 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

US11484527 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations
Mar, 2033

(8 years from now)

Viberzi is owned by Allergan Holdings.

Viberzi contains Eluxadoline.

Viberzi has a total of 20 drug patents out of which 0 drug patents have expired.

Viberzi was authorised for market use on 27 May, 2015.

Viberzi is available in tablet;oral dosage forms.

Viberzi can be used as treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline), treatment of pain associated with irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline); treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline)., treatment of pain associated with irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline), treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline)., reduction of the frequency of abdominal pain and diarrhea, in an inflammatory bowel disease with diarrhea (ibs-d) patient, with eluxadoline twice daily with food.

The generics of Viberzi are possible to be released after 14 March, 2033.

Drugs and Companies using ELUXADOLINE ingredient

Market Authorisation Date: 27 May, 2015

Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline).; Treatment of pain associated with irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline); Re...

Dosage: TABLET;ORAL

How can I launch a generic of VIBERZI before it's drug patent expiration?
More Information on Dosage

VIBERZI family patents

Family Patents